IDEXX Laboratories (NasdaqGS:IDXX) Price Moves -14% Over The Last Week Amid Market Volatility

IDEXX Laboratories (NasdaqGS:IDXX) experienced a 14% decline over the last week, in line with the broader market turmoil where the S&P 500 fell by 12% amid heightened tariff tensions between the U.S. and China. The recent market volatility, driven by the imposition of new tariffs and China’s retaliatory measures, has largely weighed on various sectors, including healthcare and technology, which impact IDEXX's operational landscape. While some sectors like technology managed gains due to company-specific factors, IDEXX's price performance seems consistent with the broader economic concerns affecting the market.

You should learn about the 1 risk we've spotted with IDEXX Laboratories.

Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

The recent decline in IDEXX Laboratories' share price reflects broader economic concerns driven by tariff tensions between the U.S. and China. Although this short-term market volatility impacts immediate sentiment, it's essential to consider IDEXX's longer-term performance. Over the past five years, total returns, including share price appreciation and dividends, have risen 37.27%. In comparison, over the last year, IDEXX underperformed both the US market and the U.S. Medical Equipment industry, which returned 5.8% and 6.3% declines respectively.

This week's market movement may affect revenue and earnings forecasts as analysts evaluate sustainability against ongoing pressures such as unfavorable exchange rates and increased operational costs. Revenue is forecast to grow by 6.9% annually while earnings are expected to increase at a rate of 8.99% per year, though these estimates could be impacted if market conditions persist. The current share price of US$418.57 sits at a discount to the analysts' price target of US$496.63, indicating potential upside if the company meets growth expectations.

Assess IDEXX Laboratories' previous results with our detailed historical performance reports.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com